Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Aug;30(2):310–314. doi: 10.1128/aac.30.2.310

Aztreonam in the treatment of severe urinary tract infections in pediatric patients.

F Rusconi, B M Assael, A Boccazzi, R Colombo, R M Crossignani, L Garlaschi, L Rancilio
PMCID: PMC180540  PMID: 3094442

Abstract

Aztreonam was administered to 30 patients, ages 0.03 to 15.4 years, with severe and in 21 cases complicated urinary tract infections caused by members of the family Enterobacteriaceae and Pseudomonas aeruginosa which were resistant to ampicillin and susceptible to the study drug in vitro. A mean dose of 47.7 mg/kg was given intramuscularly every 12 h to 26 patients. In four patients with renal insufficiency, the dose was reduced according to pharmacokinetic data. Permanent urine sterilization and clinical cure were achieved in 22 patients, 13 of whom had urological malformations. In two patients with P. aeruginosa and Proteus mirabilis infections, the treatment failed. Another patient had an Escherichia coli reinfection 21 days after the end of therapy. Four patients with various urological abnormalities had gram-positive superinfections, and two patients had gram-negative superinfections during and at the end of therapy: all six had indwelling ureteric splints or pyelostomy as predisposing conditions. No adverse clinical effects were observed. Some transient and slight or moderate alterations were observed at the end of treatment: eosinophilia (nine cases), elevation of hepatic enzymes (eight cases), prolongation of prothrombin time (three cases), and neutropenia (one case). A pharmacokinetic study was performed in six patients with normal renal function and in seven patients with various degrees of renal insufficiency. The elimination half-life of the drug was inversely correlated with the glomerular filtration rate. At the dosage used, aztreonam proved effective for severe urinary tract infections caused by members of the family Enterobacteriaceae in pediatric patients.

Full text

PDF
310

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Congeni B. L., Chonmaitree T., Rakusan T. A., Box Q. T. Once-daily ceftriaxone therapy for serious bacterial infections in children. Antimicrob Agents Chemother. 1985 Feb;27(2):181–183. doi: 10.1128/aac.27.2.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eng R. H., Smith S. M., Cherubin C. Inoculum effect of new beta-lactam antibiotics on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Jul;26(1):42–47. doi: 10.1128/aac.26.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fillastre J. P., Leroy A., Baudoin C., Humbert G., Swabb E. A., Vertucci C., Godin M. Pharmacokinetics of aztreonam in patients with chronic renal failure. Clin Pharmacokinet. 1985 Jan-Feb;10(1):91–100. doi: 10.2165/00003088-198510010-00005. [DOI] [PubMed] [Google Scholar]
  4. Freedman J. M., Hoffman S. H., Scheld W. M., Lynch M. A., da Silva H. R., Rocha H., Sande M. A. Moxalactam for the treatment of bacterial meningitis in children. J Infect Dis. 1983 Nov;148(5):886–891. doi: 10.1093/infdis/148.5.886. [DOI] [PubMed] [Google Scholar]
  5. Giamarellou H., Galanakis N., Douzinas E., Petrikkos G., El Messidi M., Papoulias G., Daikos G. K. Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up. Antimicrob Agents Chemother. 1984 Aug;26(2):245–249. doi: 10.1128/aac.26.2.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Greenberg R. N., Reilly P. M., Luppen K. L., McMillian R., Bollinger M., Wolk S. M., Darji T. B., Noorani A. A. Treatment of serious gram-negative infections with aztreonam. J Infect Dis. 1984 Nov;150(5):623–630. doi: 10.1093/infdis/150.5.623. [DOI] [PubMed] [Google Scholar]
  7. Jacobus N. V., Ferreira M. C., Barza M. In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother. 1982 Nov;22(5):832–838. doi: 10.1128/aac.22.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jodal U., Lindberg U., Lincoln K. Level diagnosis of symptomatic urinary tract infections in childhood. Acta Paediatr Scand. 1975 Mar;64(2):201–208. doi: 10.1111/j.1651-2227.1975.tb03822.x. [DOI] [PubMed] [Google Scholar]
  9. Kafetzis D. A., Brater D. C., Kanarios J., Sinaniotis C. A., Papadatos C. J. Clinical pharmacology of cefotaxime in pediatric patients. Antimicrob Agents Chemother. 1981 Oct;20(4):487–490. doi: 10.1128/aac.20.4.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaplan S. L., Mason E. O., Jr, Garcia H., Kvernland S. J., Loiselle E. M., Anderson D. C., Mintz A. A., Feigin R. D. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis. J Pediatr. 1981 Jan;98(1):152–157. doi: 10.1016/s0022-3476(81)80562-8. [DOI] [PubMed] [Google Scholar]
  11. Livermore D. M., Williams J. D. In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):29–37. doi: 10.1093/jac/8.suppl_e.29. [DOI] [PubMed] [Google Scholar]
  12. Magnussen C. R., Sammartino M. T., Ernest K. D. Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin. Antimicrob Agents Chemother. 1982 Jul;22(1):154–156. doi: 10.1128/aac.22.1.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mihindu J. C., Scheld W. M., Bolton N. D., Spyker D. A., Swabb E. A., Bolton W. K. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother. 1983 Aug;24(2):252–261. doi: 10.1128/aac.24.2.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Moellering R. C., Jr, Wennersten C., Kunz L. J., Poitras J. W. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med. 1977 Jun;62(6):873–881. doi: 10.1016/0002-9343(77)90655-6. [DOI] [PubMed] [Google Scholar]
  15. Romero-Vivas J., Rodríguez-Créixems M., Bouza E., Hellín T., Guerrero A., Martínez-Beltrán J., García de la Torre M. Evaluation of aztreonam in the treatment of severe bacterial infections. Antimicrob Agents Chemother. 1985 Aug;28(2):222–226. doi: 10.1128/aac.28.2.222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rusconi F., Assael B. M., Florioli A., Zaffaroni G. Ceftazidime in the treatment of pediatric patients with severe urinary tract infections due to Pseudomonas spp. Antimicrob Agents Chemother. 1984 Mar;25(3):395–397. doi: 10.1128/aac.25.3.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. STAMEY T. A., GOVAN D. E., PALMER J. M. THE LOCALIZATION AND TREATMENT OF URINARY TRACT INFECTIONS: THE ROLE OF BACTERICIDAL URINE LEVELS AS OPPOSED TO SERUM LEVELS. Medicine (Baltimore) 1965 Jan;44:1–36. doi: 10.1097/00005792-196501000-00001. [DOI] [PubMed] [Google Scholar]
  18. Sattler F. R., Moyer J. E., Schramm M., Lombard J. S., Appelbaum P. C. Aztreonam compared with gentamicin for treatment of serious urinary tract infections. Lancet. 1984 Jun 16;1(8390):1315–1318. doi: 10.1016/s0140-6736(84)91817-8. [DOI] [PubMed] [Google Scholar]
  19. Schwartz G. J., Feld L. G., Langford D. J. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984 Jun;104(6):849–854. doi: 10.1016/s0022-3476(84)80479-5. [DOI] [PubMed] [Google Scholar]
  20. Schwartz G. J., Haycock G. B., Edelmann C. M., Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976 Aug;58(2):259–263. [PubMed] [Google Scholar]
  21. Stutman H. R., Marks M. I., Swabb E. A. Single-dose pharmacokinetics of aztreonam in pediatric patients. Antimicrob Agents Chemother. 1984 Aug;26(2):196–199. doi: 10.1128/aac.26.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Swabb E. A., Sugerman A. A. Review of single- and multiple-dose pharmacokinetics of the monobactam, aztreonam (SQ 26,776) in healthy subjects. Chemotherapy. 1983;29(5):313–321. doi: 10.1159/000238214. [DOI] [PubMed] [Google Scholar]
  23. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wilson C. B., Koup J. R., Opheim K. E., Adelman L. A., Levy J., Stull T. L., Clausen C., Smith A. L. Piperacillin pharmacokinetics in pediatric patients. Antimicrob Agents Chemother. 1982 Sep;22(3):442–447. doi: 10.1128/aac.22.3.442. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES